Kamada Ltd. (KMDA) Expected to Post Quarterly Sales of $24.84 Million
Equities research analysts expect Kamada Ltd. (NASDAQ:KMDA) to announce sales of $24.84 million for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Kamada’s earnings, with the lowest sales estimate coming in at $24.50 million and the highest estimate coming in at $25.18 million. Kamada reported sales of $19.37 million during the same quarter last year, which indicates a positive year over year growth rate of 28.2%. The firm is scheduled to report its next quarterly earnings results on Thursday, November 9th.
On average, analysts expect that Kamada will report full year sales of $24.84 million for the current year. For the next year, analysts forecast that the firm will post sales of $126.66 million per share, with estimates ranging from $120.80 million to $132.51 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Kamada.
Kamada (NASDAQ:KMDA) last posted its earnings results on Tuesday, August 1st. The biotechnology company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.01. The firm had revenue of $32.55 million during the quarter, compared to analyst estimates of $33.30 million. Kamada had a negative net margin of 2.24% and a negative return on equity of 2.94%. The business’s quarterly revenue was up 70.7% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.04) EPS.
KMDA has been the subject of several analyst reports. Zacks Investment Research upgraded Kamada from a “sell” rating to a “hold” rating in a research note on Tuesday, August 15th. ValuEngine cut Kamada from a “hold” rating to a “sell” rating in a research note on Friday, September 1st. Jefferies Group LLC restated a “buy” rating and set a $7.00 price target on shares of Kamada in a research note on Thursday, October 12th. Finally, TheStreet cut Kamada from a “c-” rating to a “d+” rating in a research note on Tuesday, August 1st. Two analysts have rated the stock with a sell rating and two have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $8.50.
Kamada (KMDA) traded up 0.000% during trading on Thursday, hitting $4.775. 38,723 shares of the stock traded hands. The stock’s market cap is $178.59 million. Kamada has a 12 month low of $3.75 and a 12 month high of $8.61. The firm’s 50-day moving average is $4.67 and its 200-day moving average is $5.92.
Several institutional investors have recently added to or reduced their stakes in KMDA. Edmond DE Rothschild Holding S.A. raised its stake in shares of Kamada by 10.5% during the second quarter. Edmond DE Rothschild Holding S.A. now owns 42,200 shares of the biotechnology company’s stock worth $251,000 after purchasing an additional 4,000 shares during the last quarter. Navellier & Associates Inc purchased a new stake in shares of Kamada during the second quarter worth approximately $303,000. Renaissance Technologies LLC raised its stake in shares of Kamada by 16.7% during the first quarter. Renaissance Technologies LLC now owns 264,800 shares of the biotechnology company’s stock worth $1,801,000 after purchasing an additional 37,800 shares during the last quarter. Nexthera Capital LP purchased a new stake in shares of Kamada during the second quarter worth approximately $1,805,000. Finally, Vanguard Group Inc. raised its stake in shares of Kamada by 6.5% during the second quarter. Vanguard Group Inc. now owns 468,390 shares of the biotechnology company’s stock worth $2,810,000 after purchasing an additional 28,382 shares during the last quarter. Institutional investors and hedge funds own 7.29% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was originally published by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://www.watchlistnews.com/kamada-ltd-kmda-expected-to-post-quarterly-sales-of-24-84-million/1637359.html.
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.